


## Fondaparinux sodium

Cat. No.:	HY-B0597
CAS No.:	114870-03-0
Molecular Formula:	C <sub>31</sub> H <sub>43</sub> N <sub>3</sub> Na <sub>10</sub> O <sub>49</sub> S <sub>8</sub>
Molecular Weight:	1728.08
Target:	Factor Xa
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 125 mg/mL (72.33 mM); Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass			
			1 mg	5 mg	10 mg	
			1 mM	0.5787 mL	2.8934 mL	5.7868 mL
			5 mM	0.1157 mL	0.5787 mL	1.1574 mL
10 mM	0.0579 mL	0.2893 mL	0.5787 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (57.87 mM); Clear solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

Description	Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
IC <sub>50</sub> & Target	Factor Xa <sup>[1]</sup>
In Vitro	Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC <sub>50</sub> values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- Adv Sci (Weinh). 2022 Oct 18;e2203088.
- Sens Actuators B Chem. 21 September 2022, 132709.
- Patent. US20230012702A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.

[2]. Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA